Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases
Objective Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of F...
Gespeichert in:
| Veröffentlicht in: | European radiology 2013-04, Vol.23 (4), p.931-937 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 937 |
|---|---|
| container_issue | 4 |
| container_start_page | 931 |
| container_title | European radiology |
| container_volume | 23 |
| creator | Rosenbaum, Charlotte E. N. M. van den Bosch, M. A. A. J. Veldhuis, W. B. Huijbregts, J. E. Koopman, M. Lam, M. G. E. H. |
| description | Objective
Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of FDG-PET to abdominal CT and study the influence of FDG-PET findings on treatment decisions.
Methods
All consecutive patients with colorectal cancer liver metastases (CRCLM) referred for Y90-RE were included. Patients who underwent both CT and FDG-PET in the diagnostic workup were selected. Imaging reports were scrutinised for documented sites of EHD, and changes of management due to FDG-PET findings were determined.
Results
A total of 42 patients were included. Findings on CT and FDG-PET matched in 20 patients (no EHD,
n
= 15; identical EHD,
n
= 5). In 4 patients, lesions detected on CT were not FDG-avid, and in 18 patients, FDG-PET showed more lesions than CT (
P
|
| doi_str_mv | 10.1007/s00330-012-2693-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1317851464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919009691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-1b56d892d954c152eafec8aa2f524231356f855b7f8738f211ef247ed9788be3</originalsourceid><addsrcrecordid>eNp1kcuKFDEUhoMoTs_oA7iRgBs30ZxcqlLLYZyLMKCL3hfp1ElPxqpKm6Tm8g4-tGl7FBGEkATO9_8nJz8hb4B_AM7bj5lzKTnjIJhoOskenpEVKCkYcKOekxXvpGFt16kjcpzzLee8A9W-JEdCAoABsyI_TocBB3pnxwVp9PTi0yX7er6mYbLbMG9pmGm5QToEu51jLsHR-5i-LTvqY6KPpaSwTKzjNNkhRJw2cQzZlhDnvXJXbziXTO9DuaEujjGhK3akzs4OEx3DXd0nLDbXhfkVeeHtmPH103lC1hfn67Mrdv3l8vPZ6TVzshWFwUY3g-nE0GnlQAu0Hp2xVngtVB1N6sYbrTetN600XgCgF6rFoWuN2aA8Ie8PtrsUvy-YSz-F7HAc7YxxyT1IaI0G1aiKvvsHvY1LmuvjflEKtNZNpeBAuRRzTuj7XaofmB574P0-qf6QVF-T6vdJ9Q9V8_bJedlMOPxR_I6mAuIA5Fqat5j-av1f159bgp-i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1317415556</pqid></control><display><type>article</type><title>Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Rosenbaum, Charlotte E. N. M. ; van den Bosch, M. A. A. J. ; Veldhuis, W. B. ; Huijbregts, J. E. ; Koopman, M. ; Lam, M. G. E. H.</creator><creatorcontrib>Rosenbaum, Charlotte E. N. M. ; van den Bosch, M. A. A. J. ; Veldhuis, W. B. ; Huijbregts, J. E. ; Koopman, M. ; Lam, M. G. E. H.</creatorcontrib><description>Objective
Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of FDG-PET to abdominal CT and study the influence of FDG-PET findings on treatment decisions.
Methods
All consecutive patients with colorectal cancer liver metastases (CRCLM) referred for Y90-RE were included. Patients who underwent both CT and FDG-PET in the diagnostic workup were selected. Imaging reports were scrutinised for documented sites of EHD, and changes of management due to FDG-PET findings were determined.
Results
A total of 42 patients were included. Findings on CT and FDG-PET matched in 20 patients (no EHD,
n
= 15; identical EHD,
n
= 5). In 4 patients, lesions detected on CT were not FDG-avid, and in 18 patients, FDG-PET showed more lesions than CT (
P
< 0.05). In 7/42 patients (17 %) a change of management was made based on the additional FDG-PET findings, i.e. exclusion from Y90-RE treatment (
n
= 6) and change in treatment plan (whole liver rather than segmental treatment,
n
= 1).
Conclusions
In patients with CRCLM referred for Y90-RE, FDG-PET showed significantly more EHD and led to a considerable change of management.
Key Points
•
Yttrium-90 radioembolisation is a locoregional treatment for liver tumours
•
Detection of extrahepatic lesions, for which CT is widely used, is crucial
•
FDG-PET shows significantly more extrahepatic lesions compared to CT
•
FDG-PET findings led to a considerable change in treatment decisions</description><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-012-2693-x</identifier><identifier>PMID: 23111818</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Abdomen ; Adult ; Aged ; Aged, 80 and over ; Cancer therapies ; Chemotherapy ; Colorectal cancer ; Colorectal Neoplasms - diagnostic imaging ; Colorectal Neoplasms - radiotherapy ; Colorectal Neoplasms - secondary ; Diagnostic Radiology ; FDA approval ; Female ; Fluorodeoxyglucose F18 ; Humans ; Imaging ; Internal Medicine ; Interventional ; Interventional Radiology ; Liver ; Male ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neuroradiology ; Nuclear medicine ; Patients ; Positron-Emission Tomography - methods ; Prognosis ; Radiology ; Radiopharmaceuticals - therapeutic use ; Reproducibility of Results ; Sensitivity and Specificity ; Tomography ; Treatment Outcome ; Tumors ; Ultrasound ; Yttrium Radioisotopes - therapeutic use</subject><ispartof>European radiology, 2013-04, Vol.23 (4), p.931-937</ispartof><rights>European Society of Radiology 2012</rights><rights>European Society of Radiology 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-1b56d892d954c152eafec8aa2f524231356f855b7f8738f211ef247ed9788be3</citedby><cites>FETCH-LOGICAL-c372t-1b56d892d954c152eafec8aa2f524231356f855b7f8738f211ef247ed9788be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00330-012-2693-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00330-012-2693-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23111818$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenbaum, Charlotte E. N. M.</creatorcontrib><creatorcontrib>van den Bosch, M. A. A. J.</creatorcontrib><creatorcontrib>Veldhuis, W. B.</creatorcontrib><creatorcontrib>Huijbregts, J. E.</creatorcontrib><creatorcontrib>Koopman, M.</creatorcontrib><creatorcontrib>Lam, M. G. E. H.</creatorcontrib><title>Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><addtitle>Eur Radiol</addtitle><description>Objective
Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of FDG-PET to abdominal CT and study the influence of FDG-PET findings on treatment decisions.
Methods
All consecutive patients with colorectal cancer liver metastases (CRCLM) referred for Y90-RE were included. Patients who underwent both CT and FDG-PET in the diagnostic workup were selected. Imaging reports were scrutinised for documented sites of EHD, and changes of management due to FDG-PET findings were determined.
Results
A total of 42 patients were included. Findings on CT and FDG-PET matched in 20 patients (no EHD,
n
= 15; identical EHD,
n
= 5). In 4 patients, lesions detected on CT were not FDG-avid, and in 18 patients, FDG-PET showed more lesions than CT (
P
< 0.05). In 7/42 patients (17 %) a change of management was made based on the additional FDG-PET findings, i.e. exclusion from Y90-RE treatment (
n
= 6) and change in treatment plan (whole liver rather than segmental treatment,
n
= 1).
Conclusions
In patients with CRCLM referred for Y90-RE, FDG-PET showed significantly more EHD and led to a considerable change of management.
Key Points
•
Yttrium-90 radioembolisation is a locoregional treatment for liver tumours
•
Detection of extrahepatic lesions, for which CT is widely used, is crucial
•
FDG-PET shows significantly more extrahepatic lesions compared to CT
•
FDG-PET findings led to a considerable change in treatment decisions</description><subject>Abdomen</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - diagnostic imaging</subject><subject>Colorectal Neoplasms - radiotherapy</subject><subject>Colorectal Neoplasms - secondary</subject><subject>Diagnostic Radiology</subject><subject>FDA approval</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Interventional</subject><subject>Interventional Radiology</subject><subject>Liver</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neuroradiology</subject><subject>Nuclear medicine</subject><subject>Patients</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prognosis</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Tomography</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Ultrasound</subject><subject>Yttrium Radioisotopes - therapeutic use</subject><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kcuKFDEUhoMoTs_oA7iRgBs30ZxcqlLLYZyLMKCL3hfp1ElPxqpKm6Tm8g4-tGl7FBGEkATO9_8nJz8hb4B_AM7bj5lzKTnjIJhoOskenpEVKCkYcKOekxXvpGFt16kjcpzzLee8A9W-JEdCAoABsyI_TocBB3pnxwVp9PTi0yX7er6mYbLbMG9pmGm5QToEu51jLsHR-5i-LTvqY6KPpaSwTKzjNNkhRJw2cQzZlhDnvXJXbziXTO9DuaEujjGhK3akzs4OEx3DXd0nLDbXhfkVeeHtmPH103lC1hfn67Mrdv3l8vPZ6TVzshWFwUY3g-nE0GnlQAu0Hp2xVngtVB1N6sYbrTetN600XgCgF6rFoWuN2aA8Ie8PtrsUvy-YSz-F7HAc7YxxyT1IaI0G1aiKvvsHvY1LmuvjflEKtNZNpeBAuRRzTuj7XaofmB574P0-qf6QVF-T6vdJ9Q9V8_bJedlMOPxR_I6mAuIA5Fqat5j-av1f159bgp-i</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Rosenbaum, Charlotte E. N. M.</creator><creator>van den Bosch, M. A. A. J.</creator><creator>Veldhuis, W. B.</creator><creator>Huijbregts, J. E.</creator><creator>Koopman, M.</creator><creator>Lam, M. G. E. H.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130401</creationdate><title>Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases</title><author>Rosenbaum, Charlotte E. N. M. ; van den Bosch, M. A. A. J. ; Veldhuis, W. B. ; Huijbregts, J. E. ; Koopman, M. ; Lam, M. G. E. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-1b56d892d954c152eafec8aa2f524231356f855b7f8738f211ef247ed9788be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - diagnostic imaging</topic><topic>Colorectal Neoplasms - radiotherapy</topic><topic>Colorectal Neoplasms - secondary</topic><topic>Diagnostic Radiology</topic><topic>FDA approval</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Interventional</topic><topic>Interventional Radiology</topic><topic>Liver</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neuroradiology</topic><topic>Nuclear medicine</topic><topic>Patients</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prognosis</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Tomography</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Ultrasound</topic><topic>Yttrium Radioisotopes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenbaum, Charlotte E. N. M.</creatorcontrib><creatorcontrib>van den Bosch, M. A. A. J.</creatorcontrib><creatorcontrib>Veldhuis, W. B.</creatorcontrib><creatorcontrib>Huijbregts, J. E.</creatorcontrib><creatorcontrib>Koopman, M.</creatorcontrib><creatorcontrib>Lam, M. G. E. H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenbaum, Charlotte E. N. M.</au><au>van den Bosch, M. A. A. J.</au><au>Veldhuis, W. B.</au><au>Huijbregts, J. E.</au><au>Koopman, M.</au><au>Lam, M. G. E. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases</atitle><jtitle>European radiology</jtitle><stitle>Eur Radiol</stitle><addtitle>Eur Radiol</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>23</volume><issue>4</issue><spage>931</spage><epage>937</epage><pages>931-937</pages><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Objective
Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of FDG-PET to abdominal CT and study the influence of FDG-PET findings on treatment decisions.
Methods
All consecutive patients with colorectal cancer liver metastases (CRCLM) referred for Y90-RE were included. Patients who underwent both CT and FDG-PET in the diagnostic workup were selected. Imaging reports were scrutinised for documented sites of EHD, and changes of management due to FDG-PET findings were determined.
Results
A total of 42 patients were included. Findings on CT and FDG-PET matched in 20 patients (no EHD,
n
= 15; identical EHD,
n
= 5). In 4 patients, lesions detected on CT were not FDG-avid, and in 18 patients, FDG-PET showed more lesions than CT (
P
< 0.05). In 7/42 patients (17 %) a change of management was made based on the additional FDG-PET findings, i.e. exclusion from Y90-RE treatment (
n
= 6) and change in treatment plan (whole liver rather than segmental treatment,
n
= 1).
Conclusions
In patients with CRCLM referred for Y90-RE, FDG-PET showed significantly more EHD and led to a considerable change of management.
Key Points
•
Yttrium-90 radioembolisation is a locoregional treatment for liver tumours
•
Detection of extrahepatic lesions, for which CT is widely used, is crucial
•
FDG-PET shows significantly more extrahepatic lesions compared to CT
•
FDG-PET findings led to a considerable change in treatment decisions</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23111818</pmid><doi>10.1007/s00330-012-2693-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0938-7994 |
| ispartof | European radiology, 2013-04, Vol.23 (4), p.931-937 |
| issn | 0938-7994 1432-1084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1317851464 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Abdomen Adult Aged Aged, 80 and over Cancer therapies Chemotherapy Colorectal cancer Colorectal Neoplasms - diagnostic imaging Colorectal Neoplasms - radiotherapy Colorectal Neoplasms - secondary Diagnostic Radiology FDA approval Female Fluorodeoxyglucose F18 Humans Imaging Internal Medicine Interventional Interventional Radiology Liver Male Medicine Medicine & Public Health Metastasis Middle Aged Neuroradiology Nuclear medicine Patients Positron-Emission Tomography - methods Prognosis Radiology Radiopharmaceuticals - therapeutic use Reproducibility of Results Sensitivity and Specificity Tomography Treatment Outcome Tumors Ultrasound Yttrium Radioisotopes - therapeutic use |
| title | Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A53%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Added%20value%20of%20FDG-PET%20imaging%20in%20the%20diagnostic%20workup%20for%20yttrium-90%20radioembolisation%20in%20patients%20with%20colorectal%20cancer%20liver%20metastases&rft.jtitle=European%20radiology&rft.au=Rosenbaum,%20Charlotte%20E.%20N.%20M.&rft.date=2013-04-01&rft.volume=23&rft.issue=4&rft.spage=931&rft.epage=937&rft.pages=931-937&rft.issn=0938-7994&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-012-2693-x&rft_dat=%3Cproquest_cross%3E2919009691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1317415556&rft_id=info:pmid/23111818&rfr_iscdi=true |